Approved for use through 11/30/2008, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	09/767,370-Conf. #2716	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	January 23, 2001	
				First Named Inventor	Jeffrey L. BROWNING	
(Use as many sheets as necessary)				Art Unit	1643	
			s necessary)	Examiner Name	C. H. Yaen	
Sheet	1	of	1	Attorney Docket Number BGG-A054RCE3		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2 ( if known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	

NON PATENT LITERATURE DOCUMENTS    Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of						
Examiner Initials	Cite No. <sup>1</sup>	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	C1	Bowen, M.A. et al., "Structure and Expression of Murine CD30 and Its Role in Cytokine Production," <i>The Journal Of Immunology</i> , Vol. 156:442-449 (1996)				
	C2	Corcoran, A.E. et al., "Minimal tumor necrosis factor receptor binding protein: optimum biological activity of a truncated p55 soluble tumor necrosis factor receptor-lgG fusion protein," <i>European Cytokine Network</i> , Vol. 9(3):255-62 (1998)				
	СЗ	Zhai, Y. et al., "LIGHT, A Novel Ligand for Lymphotoxin Beta Receptor and TR2/HVEM Induces Apoptosis and Suppresses In Vivo Tumor Formation Via Gene Transfer," <i>J. Clin. Invest.</i> , Vol. 102(6):1142-1151 (1998)				
	C4	Forster, S.J. et al.,"Expression of Foreign Genes in Mammalian Cells Using an Antibody Fusion System," <i>Mol. Biotechnol.</i> , Vol.1(3):251-63 (2004)				
			_			

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: December 8, 2008 Electronic Signature for Cristin Howley Cowles, Ph.D.: /Cristin Howley Cowles/